Pulmonary hypertension

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced that the company has voluntarily ended its Phase 2b trial of pemziviptadil (PB1046) in PAH due to COVID-19 impacts on manufacturing, …